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Abstract
 Objective—To compare short and long term cardiovascular disease (CVD) risk scores and 
prevalence of metabolic syndrome in HIV-infected adults receiving and not receiving antiretroviral 
therapy (ART) to HIV-negative controls.
 Methods—A cross-sectional study including: 151 HIV-infected, ART-naive, 150 HIV-infected 
on ART and 153 HIV-negative adults. Traditional cardiovascular risk factors were determined by 
standard investigations. The primary outcome was ACC/AHA ASCVD Risk Estimator lifetime 
CVD risk score. Secondary outcomes were ASCVD 10-year risk, Framingham risk scores, statin 
indication and metabolic syndrome.
 Results—Compared to HIV-negative controls, more HIV-infected adults on ART were 
classified as high lifetime CVD risk (34.7% vs 17.0%, p<0.001) although 10-year risk scores were 
similar, a trend which was similar across multiple CVD risk models. In addition, HIV-infected 
adults on ART had a higher prevalence of metabolic syndrome vs HIV-negative controls (21.3% vs 
7.8%, p=0.008), with 2 common clusters of risk factors. More than one-quarter (28.7%) of HIV-
infected Tanzanian adults on ART meet criteria for statin initiation.
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 Conclusions—HIV-infected ART-treated individuals have high lifetime cardiovascular risk, 
and this risk seems to develop rapidly in the first 3–4 years of ART as does the development of 
clusters of metabolic syndrome criteria. These data identify a new subgroup of low short-term/
high lifetime risk HIV-infected individuals on ART who do not currently meet criteria for CVD 
risk factor modification but require further study.
Keywords
global health; global disease patterns; cardiac risk factors and prevention; metabolic syndrome; 
systemic inflammatory diseases
 BACKGROUND
Data from the US and Europe indicate that HIV-infected adults have a higher incidence of 
cardiovascular disease. HIV-infected adults have a 2-fold increased incidence of myocardial 
infarction [1,2] and stroke [3], and a 4-fold increased rate of sudden cardiac death [4]. The 
reason for the increased cardiovascular disease (CVD) risk in HIV-infected populations is 
poorly understood but is likely due to a complex interaction between traditional CVD risk 
factors, drug toxicity of antiretroviral therapy (ART), chronic inflammation and immune 
activation [5]. Most research has focused on short-term CVD risk but less attention has been 
paid to long-term risk in HIV-infected adults.
Although 90% of HIV-infected adults live in sub-Saharan Africa (SSA), little is known 
about CVD risk profiles among the HIV-infected adults in this region [6,7]. Cardiovascular 
risk factors such as hypertension (HTN) [8,9] and diabetes mellitus (DM) [10] are common 
among HIV-infected African adults, and CVD risk calculation tools specifically tailored to 
this population are needed[11]. One recent study reported a 10-year Framingham risk score 
of >10% in 10% of HIV-infected Ugandan adults [12]. To the best of our knowledge, no 
published study has yet quantitated the differences in CVD risk profiles between African 
HIV-infected adults on long-term ART as compared to both HIV-negative adults and to those 
starting ART.
Therefore, we conducted a controlled cross-sectional, analytical study to compare CVD risk 
profiles of HIV-infected Tanzanian adults on ART, HIV-infected ART-naïve adults and HIV-
negative adults. The objectives of this study were: 1) to quantitate and compare long and 
short-term CVD risk scores between groups, 2) to compare clustering of cardiovascular risk 
factors as defined by metabolic syndrome and 3) to determine the proportion of each 
population who met criteria for statin initiation. Our primary outcomes were American 
College of Cardiology (ACC/AHA) Atherosclerotic Cardiovascular Disease (ASCVD) 
lifetime and 10-year risk scores but we also calculated Framingham 10 and 30-year both 
with and without lipid criteria for the sake of comparison. We hypothesized that the 
proportion of the population at high lifetime risk according to ASCVD scores would be two-
fold greater among HIV-infected adults on ART compared to HIV-negative controls.
Kingery et al. Page 2
Heart. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 METHODS
 Study design
This was an analytical, controlled cross-sectional study.
 Study area
The study was conducted between October 2012 and April 2013 in the outpatient HIV clinic 
of the Bugando Medical Centre (BMC) in Mwanza, Tanzania. BMC is the zonal hospital for 
the Lake Victoria Zone in northwest Tanzania, serving a population of approximately 13 
million. The HIV prevalence in the Lake Zone is 6%, similar to the national average of 5.1%
[13]. At the time of the study, the BMC HIV clinic was providing care to 14,432 patients of 
whom 9,064 are currently receiving ART. Patients are referred to BMC from surrounding 
community-based voluntary counseling and testing centers in the city of Mwanza. 
According to Tanzanian national guidelines, all HIV-infected patients must be assigned a 
treatment partner who is typically a family member, friend or partner. HIV-infected patients 
fulfilling Tanzanian national criteria for ART are started on treatment and are seen monthly 
or bi-monthly at the BMC clinic. At the time of the study, Tanzanian criteria for starting 
ART included World Health Organization (WHO) Clinical Stage III disease with CD4 count 
<350 cells/μl, Stage IV disease regardless of CD4 count, or CD4 count <200 cells/μl. The 
first-line ART regimen consisted of either tenofivir/emcitrabine or zidovudine/lamivudine + 
nevirapine or efavirenz. Protease inhibitors (PIs) were only given as second-line ART, in 
accordance with Tanzanian national guidelines [14].
 Study population
All of the study population was recruited from the BMC HIV clinic. The study included 3 
groups of adults (all >18 years old) for the purpose of comparisons:
1. HIV-infected adults on ART for ≥2 years (HIV-infected, on ART),
2. HIV-infected adults newly establishing care in last 3 months, not yet on 
ART (HIV-infected, ART-naïve) &
3. HIV-negative adult treatment partners (control group).
HIV-negative adult treatment partners were chosen as a control group in order to provide a 
population with similar socioeconomic status to the 2 groups of HIV-infected adults. All 
treatment partners who attended the BMC HIV clinic during the study period were eligible 
for enrollment. Exclusion criteria included pregnancy and failure to attend a follow-up visit 
on the day after enrollment.
 Laboratory analysis
At enrolment, blood samples were obtained and the CD4 count was measured using an 
automated BD FACS Calibur Machine (BD Biosciences, San Jose, CA, USA). A urine 
pregnancy test was performed on women whose last menstrual period was >1 month prior to 
the date of interview. Enrolled study subjects were instructed to return to the clinic the 
following morning after an overnight fast.
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All participants underwent an oral glucose tolerance test (OGTT) according to WHO 
protocol [15]. After an overnight fast for >8 hours, fasting blood glucose levels were 
measured from a sterile finger prick blood sample using an automated machine (OneTouch 
Select, LifeScan, CA, USA). The OneTouch Select reports a plasma glucose equivalent and 
has been shown to be >90% accurate (compared to venous plasma glucose measurement) in 
diagnosing diabetes mellitus when used for OGTT in resource-limited settings [16]. Each 
participant was then given 400mls of Lucozade (Glaxo Smith-Kline, London, UK), which is 
equivalent to 75g glucose loading dose in water, over a duration of <5 minutes [17]. Blood 
glucose levels were measured again, 2 hours after ingestion of glucose.
Total cholesterol, high density lipoprotein (HDL) cholesterol, and triglycerides levels were 
measured using Cobas Integra 400 Plus Analyzer (Roche Diagnostic Limited, Switzerland). 
Low density lipoprotein (LDL) levels were calculated using the Friedewald equation [18]. 
LDL levels could not be calculated for one HIV-negative patient because the triglyceride 
level exceeded 4.52 mmol/L.
 Definitions
Ten year cardiovascular risk scores were determined using three equations: Framingham risk 
score with lipids, Framingham risk score without lipid levels [19], and 2013 ASCVD [20]. 
ASCVD 10-year risk was calculated using the published formula and including the actual 
age of the patient. As a sensitivity analysis, we also calculated scores designating those <40 
years of age as 40 years old and excluding those with age <40 years. These sensitivity 
analysis, as expected, did lead to an increase in predicted risk but did not change the overall 
results or conclusions of the study. Long-term cardiovascular risk scores were calculated 
using three equations: Framingham 30-year risk formulas using either lipids or body mass 
index (BMI) [21] and ASCVD lifetime risk. For Framingham risk scores we determined the 
proportion of each group with low, intermediate, and high risk, which was defined as <10%, 
between 10 and 20%, and ≥20%, respectively [22]. ASCVD lifetime risk scores were 
stratified into subgroups published in recent literature and referenced in the 2013 ACC/AHA 
guidelines [23].
We determined the proportion of individuals indicated for statin therapy according to the 
ASCVD guidelines: current CVD, LDL >=4.91mmol/L (190mg/dL), diabetes and aged 40–
75 years, or 10-year cardiovascular risk >=7.5% aged 40–75 years [24].
Diabetes mellitus (DM) used in the CVD risk equations was defined as either a fasting blood 
glucose ≥7.0mol/l (126mg/dL) or a glucose level ≥11.1mol/l (200mg/dL) 2 hours after a 75g 
oral glucose load [15]. We determined the prevalence of metabolic syndrome according to 
both ATPIII and International Diabetes Federation (IDF) definitions. Specifically, ATPIII 
criteria are three or more of the following: 1) waist circumference >88cm or 102cm in 
women and men, respectively, 2) triglycerides >150mg/dl, 3) HDL <50mg/dl or <40mg/dl in 
women and men, respectively, 4) blood pressure >130/85 and 5) fasting glucose >110mg/dl. 
IDF metabolic syndrome was defined as central obesity plus two of the following: 1) 
triglycerides >150mg/dl, 2) triglycerides >150mg/dl, 3) HDL <50mg/dl or <40mg/dl in 
women and men, respectively, 4) blood pressure >130/85 and 5) fasting glucose >100mg/dl 
[25,26].
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 Statistical Analysis
The primary outcomes of the study were lifetime and 10-year cardiovascular risk as per 
ASCVD guidelines. The primary study analysis was comparison of stratified lifetime and 
10-year CVD risk scores between each HIV-infected group and the HIV-negative control 
group. We hypothesized that 50% of HIV-infected on ART vs 30% of HIV-negative controls 
would be classified as high lifetime CVD risk according to the ASCVD categories. We 
calculated that a sample size of >150 per group would provide >90% power to detect this 
difference. Sample size was calculated in Stata using two sample proportions chi squared 
test and significance was determined with a two-sided p value of <0.05.
Data analysis was done using STATA version 14 (San Antonio, Texas). Descriptive statistics 
were computed by determining mean and standard deviation for continuous variables and 
proportions (percentages) for categorical variables. Logistic regression for binary variables 
and ordinal logistic regression for ordered categorical outcomes. Ordinal logistic regression 
was used to compare ordinal outcomes, such as categories of cardiovascular risk. P-values 
were obtained from the likelihood ratio test, with those less than 0.05 considered significant. 
There were four missing values for the “treated hypertension” variable, which represents 
0.8% of that variable. No other variables had missing values.
 Ethics Statement
The study was approved by the Institutional Review Boards at Bugando Medical Centre and 
Weill Cornell Medical College. All study participants were informed about the study by a 
nurse or doctor fluent in Kiswahili and provided written informed consent before 
participation. All results were made available to clinicians and recorded in the patients’ files. 
Disease management was conducted by the health care workers of the HIV clinic according 
to Bugando Medical Centre and Tanzanian management protocols and practices.
 RESULTS
 Enrollment
During the study period, 488 adults were screened and 34 were excluded from the study: 7 
patients were found to be pregnant (4 HIV-infected on ART and 3 HIV-infected ART-naïve), 
and 27 did not return the following day (7 HIV-infected on ART, 9 HIV-infected treatment 
naïve and 11 HIV-negative controls). Therefore, a total of 454 adults were enrolled: 150 
HIV-infected adults on ART, 151 HIV-infected treatment naive and 153 HIV-negative 
controls.
 Baseline characteristics
The characteristics of the 3 groups are described in Table 1. Compared to the control group 
(age 40.5 years, 61.4% female) HIV-infected adults ART naïve and on ART were 
statististically similar in age (38.5 and 42.6 years, p=0.084 and 0.067, respectively), but 
HIV-infected on ART adults were more likely to be female (76.7%, p=0.002). Other notable 
differences included a higher prevalence of central obesity, diabetes mellitus and 
hypertension but a lower prevalence of smoking in the HIV infected patients on ART than 
the HIV negative control group. HIV-infected, ART-naïve adults had lower mean BMI and 
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were more severely immunosuppressed (mean CD4 T-cell count 247.6 (184.4) cells/μL vs. 
406.6 (197.9) cells/μL in the group on ART). HIV-infected adults on ART had been using 
ART for a mean of 53.1 (21.6) months.
 Cardiovascular Risk
Tables 2 and 3 display the ASCVD and Framingham risk categories, respectively. Stratified 
lifetime cardiovascular risk was significantly higher in HIV-infected on ART as compared to 
HIV-negative (Table 2). The proportion of study participants with high lifetime risk 
according to ASCVD (high risk if >=1 major risk factor) was 52/150 (34.7%) in the HIV-
infected adults on ART vs. 26/153 (17.0%) in the control group (p<0.001). Additionally, the 
proportion of participants with high 30-year Framingham risk was significantly greater in 
the HIV-infected adults on ART as compared to HIV-negative controls (19.3% vs 13.1% 
respectively, p=0.047) when using lipid-based formulas (Table 3). HIV-infected treatment 
naïve participants had significantly lower ASCVD lifetime and 10-year risk scores (p=0.04 
and 0.01, respectively). Per ASCVD guidelines, statin therapy was indicated in 28.7% 
(43/150) of HIV-infected adults on ART, 10.6% (16/151) of HIV-infected treatment naïve 
adults and 20.3% (31/153) of HIV-negative controls.
Of note, significantly more HIV-infected adults on ART (64/150 [42.7%], p=0.045) and 
fewer HIV-infected ART naïve (26/151 [17.2%], p=0.004) adults fit into a “low 10 year/high 
lifetime” risk category as compared to HIV-negative (48/153 [31.4%]).
 Prevalence of Metabolic Syndrome
Significantly more HIV-infected adults on ART had metabolic syndrome compared to HIV-
negative controls (Table 4). According to the ASCVD definition, 17/150 (11.3%) HIV-
infected adults on ART had metabolic syndrome 5/153 (3.3%) compared to HIV-negative 
controls (p=0.01). Metabolic syndrome as defined by IDF criteria yielded similar results. Of 
the 17 HIV-infected adults on ART who met the ASCVD criteria for metabolic syndrome 10 
met three criteria and two met four criteria. None met high triglyceride criteria. Proportions 
of those with metabolic syndrome according to ASCVD who met individual criteria were: 
high blood pressure (15/17 (88.2%)), low HDL (14/17 (82.4%)), high waist circumference 
(13/17 (76.8%)), and high fasting blood glucose (11/17 (64.7%)). The most common risk 
factor clusters were the combination of waist circumference, low HDL and high blood 
pressure (6 of 17) and high glucose, low HDL and high blood pressure (4 of 17). Other 
clusters of risk factors were equally distributed.
 DISCUSSION
In our study, the first to compare long-term ASCVD risk scores in HIV-infected and HIV-
negative adults in Africa, the long-term predicted ASCVD risk scores were significantly and 
consistently higher among HIV-infected adults on ART compared to HIV-negative controls 
by multiple calculations. More than a third of HIV-infected adults on ART fit into the two 
highest ASCVD lifetime risk groups, corresponding to a predicted lifetime risk >37%. 
Similarly, nearly 50% of HIV-infected, on ART study adults had intermediate or high 
Kingery et al. Page 6
Heart. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Framingham 30-year risk as compared to one third of HIV-negative controls. In contrast, 
predicted 10-year ASCVD risk scores were relatively low and similar in all groups.
HIV-infected, ART naïve adults, on the other hand, had significantly lower long-term 
predicted CVD risk scores than HIV-uninfected controls. These data seem to indicate that, 
among HIV-infected African adults, CVD risk profiles increase dramatically in the first 3–4 
years of ART, a finding that is supported by our data regarding metabolic syndrome. 
Longitudinal studies are needed to test this important hypothesis. In addition, this apparent 
rapid accumulation of CVD risk factors indicates a dynamic population that deserves public 
health attention. Systems must be put in place to assure that regular screening for CVD risk 
factors occurs frequently for HIV-infected adults during the first several years of ART. This 
is particularly important since our prior reports have indicated that very few of these HIV-
infected adults on ART had received even basic investigations for hypertension and diabetes 
[9,27].
It is possible that cardiovascular risk prediction tools underestimate risks in some high-risk 
groups, specifically in HIV-infected populations who have elevated MI risks [7]. 
Interestingly, we are the first to report that a significant proportion of HIV-infected adults on 
ART in our study, a group also proven to have both higher predicted cardiovascular risk and 
higher cardiovascular outcomes than actually predicted, fit into the category of low 10-year 
risk but high lifetime risk. This category has been proven to have higher atherosclerotic risk 
in non-HIV populations [28,29], but has received limited attention in previous studies of 
CVD disease in HIV adults. The relatively young age of both our study population and HIV-
infected African adults in general is of critical importance since age is the factor most 
strongly weighted in most cardiovascular risk prediction scores. This category of adults will 
continue to grow in importance as HIV-infected African adults live longer on ART. Further 
study of this group is urgently needed and may provide a valuable subgroup of HIV-infected 
patients from which to gain valuable insights into adjustment of current cardiovascular risk 
models.
Metabolic syndrome was significantly more prevalent in HIV-infected on ART participants 
in our study as compared to HIV-negative. In addition, we found that 60% of participants in 
this group exhibit one of only two risk factor cluster groups. High blood pressure was the 
most commonly associated criteria, with 88% of metabolic syndrome patients exhibiting 
HTN. This finding suggests that close monitoring of hypertension may provide a simple, 
effective strategy for metabolic syndrome surveillance in low-resource settings. HIV-
infected adults with high blood pressure would then deserve careful investigation for other 
risk factors.
Our study is also the first to report the prevalence of HIV-negative and positive subgroups in 
LMIC settings currently indicated for statin initiation for risk factor modification per the 
recently established ACC/AHA guidelines [20]. We show that according to current 
guidelines, ~30% of the HIV-infected adults on ART meet criteria for statin therapy. Statins 
are now available in most developing countries after recent changes in the WHO essential 
drug list, but the most widely available statin in Africa (simvastatin) is contraindicated in 
most patients on ART due to drug-drug interactions. Statins with lower risk of drug-drug 
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interaction (such as pravastatin) should be added to the WHO List of Essential Medicines 
and made available in HIV clinics in Africa.
Limitations exist in this study. While the similarity of findings between multiple short and 
long-term risk scores support our findings, it should be noted that these scores may not be 
accurate in our population. The Framingham risk model in particular, derived from a 
population of mostly white men in a limited geographic region in the northeastern US, may 
not be generalizable to our study subjects. Clearly more work is needed to validate existing 
CVD risk models and/or develop new models for HIV-infected African adults. In addition, 
while our cross-sectional study generates many interesting hypotheses, longitudinal and 
interventional studies are now needed to test these hypotheses. Finally, post-partum women 
were included in this study but we did not record data regarding prior pregnancies. Such data 
should be included in future studies.
In conclusion, HIV-infected ART treated persons in our Tanzanian study group had a 
significantly higher lifetime cardiovascular risk compared to HIV-negative adults. In 
addition, two important high risk subgroups were identified among HIV-infected adults on 
ART: 1) those with low 10 year/high lifetime CVD risk according to ASCVD guidelines 
who are currently receiving little preventive attention and 2) particular patterns of metabolic 
syndrome clustered groups. Nearly 30% of HIV-infected Tanzanian adults on ART had 
indications to start statin therapy. In addition, CV risk seems to increase rapidly after the 
time of ART initiation. Together, these findings indicate that HIV-infected African adults 
deserve careful monitoring for the development of CVD risk factors in the first few years 
after ART initiation. New CVD risk factors should be treated quickly and aggressively, 
although care must be taken with regard to possible drug-drug interactions. Further research 
is needed to determine the best approach to adults with low 10-year but high lifetime CVD 
risk.
 Acknowledgments
This project was supported by National Institutes of Health (NIH) Research Training Grant R25 TW009337, funded 
by the Fogarty International Center, the NIH Office of the Director, the National Institute of Mental Health, and the 
National Institute of Diabetes and Digestive and Kidney Diseases. Additionally, the study was supported by grants 
from the National Institutes of Health Fogarty Foundation (TW000018 and K01 TW010281-01) and the National 
Institute of Allergy and Infectious Diseases (K24 AI098627). The study sponsor was not involved in the design or 
conduct of the study; collection, management, analysis, or interpretation of the data; or in the preparation, review or 
approval of the manuscript. We would like to thank Professor Kien Mteta, the Director General of Bugando Medical 
Centre, for his administrative support in this study.
 ABBREVIATIONS
ACC American College of Cardiology
AHA American Heart Association
ART antiretroviral therapy
ASCVD 2013 ACC/AHA ASCVD Risk Estimator Guidelines
ATP adult treatment panel
Kingery et al. Page 8
Heart. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
BMC Bugando Medical Centre
CVD cardiovascular disease
DM diabetes mellitus
HDL high density lipoprotein
HTN hypertension
IDF International Diabetes Foundation
LDL low density lipoprotein
OGTT oral glucose tolerance test
SSA sub-Saharan Africa
TC total cholesterol
WHO World Health Organization
References
1. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular 
risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 
2007; 92:2506–12. DOI: 10.1210/jc.2006-2190 [PubMed: 17456578] 
2. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with 
HIV: A systematic review and meta-analysis. HIV Med. 2012; 13:453–68. DOI: 10.1111/j.
1468-1293.2012.00996.x [PubMed: 22413967] 
3. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and 
without HIV: a Danish nationwide population-based cohort study. AIDS. 2011; 25:1637–46. DOI: 
10.1097/QAD.0b013e3283493fb0 [PubMed: 21646903] 
4. Tseng Z, Secemsky E, Dowdy D, et al. Sudden cardiac death in patients with human 
immunodeficiency virus infection. J Am Coll Cardiol. 2012; 59:1891–6. [PubMed: 22595409] 
5. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012; 
9:139–47. DOI: 10.1007/s11904-012-0118-8 [PubMed: 22528766] 
6. Ali MK, Magee MJ, Dave JA, et al. HIV and Metabolic, Body, and Bone Disorders: What We Know 
From Low- and Middle-Income Countries. J Acquir Immune Defic Syndr. 2014; 67(Suppl 1):S27–
39. DOI: 10.1097/QAI.0000000000000256 [PubMed: 25117959] 
7. Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013; 10:199–206. 
DOI: 10.1007/s11904-013-0168-6 [PubMed: 23793823] 
8. Barninghausen T, Welze T, Hosegood V, et al. Hiding in the shadows of the HIV epidemic: obesity 
and hypertension in a rural population with very high HIV prevalence in South Africa. J Hum 
Hypertens. 2008; 22:236–9. DOI: 10.1038/sj.jhh.1002308 [PubMed: 18046436] 
9. Peck RN, Shedafa R, Kalluvya S, et al. Hypertension, kidney disease, HIV and antiretroviral therapy 
among Tanzanian adults: a cross-sectional study. BMC Med. 2014; 12:125.doi: 10.1186/
s12916-014-0125-2 [PubMed: 25070128] 
10. Kengne AP, Echouffo-Tcheugui J-B, Sobngwi E, et al. New insights on diabetes mellitus and 
obesity in Africa-Part 1: prevalence, pathogenesis and comorbidities. Heart. 2013; 99:979–83. 
DOI: 10.1136/heartjnl-2012-303316 [PubMed: 23680891] 
11. D’Agostino RB. Cardiovascular risk estimation in 2012: Lessons learned and applicability to the 
HIV population. J Infect Dis. 2012; 205(SUPPL):S362–7. DOI: 10.1093/infdis/jis196 [PubMed: 
22577209] 
Kingery et al. Page 9
Heart. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Mateen FJ, Kanters S, Kalyesubula R, et al. Hypertension prevalence and Framingham risk score 
stratification in a large HIV-positive cohort in Uganda. J Hypertens. 2013; 31:1372–8. DOI: 
10.1097/HJH.0b013e328360de1c [PubMed: 23615323] 
13. TACAIDS. HIV/AIDS and Malaria Indicator Survey 2011−12. Dar es Salaam, Tanzania: 2013. 
http://www.tacaids.go.tz/
14. National AIDS Control Programme. National Guidelines for the Management of HIV/AIDS. 3rd. 
Dar es Salaam, Tanzania: 2009. 
15. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate 
Hyperglycaemia: Report of a WHO/IDF Consultation. Geneva, Switzerland: World Health 
Organization; 2006. 
16. Priya M, Mohan Anjana R, Pradeepa R, et al. Comparison of capillary whole blood versus venous 
plasma glucose estimations in screening for diabetes mellitus in epidemiological studies in 
developing countries. Diabetes Technol Ther. 2011; 13:586–91. DOI: 10.1089/dia.2010.0218 
[PubMed: 21406012] 
17. Frost GS, Goff LM, Hamilton G, et al. Carbohydrate-induced manipulation of insulin sensitivity 
independently of intramyocellular lipids. Br J Nutr. 2003; 89:365–75. DOI: 10.1079/BJN2002789 
[PubMed: 12628032] 
18. Tremblay AJ, Morrissette H, Gagné JM, et al. Validation of the Friedewald formula for the 
determination of low-density lipoprotein cholesterol compared with β-quantification in a large 
population. Clin Biochem. 2004; 37:785–90. DOI: 10.1016/j.clinbiochem.2004.03.008 [PubMed: 
15329317] 
19. Framingham Heart Study. 10-year Framingham cardiovascular risk scores. https://
www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php
20. Goff DC, Lloyd-Jones DM, Bennett G, et al. ACC/AHA guideline on the assessment of 
cardiovascular risk: A report of the American college of cardiology/American heart association 
task force on practice guidelines. Circulation. 2013; 2014; 129doi: 10.1161/01.cir.
0000437741.48606.98
21. Pencina MJ, D’Agostino RB, Larson MG, et al. Predicting the 30-year risk of cardiovascular 
disease: The framingham heart study. Circulation. 2009; 119:3078–84. DOI: 10.1161/
CIRCULATIONAHA.108.816694 [PubMed: 19506114] 
22. Tattersall MC, Gangnon RE, Karmali KN, et al. Women Up, Men Down: The Clinical Impact of 
Replacing the Framingham Risk Score with the Reynolds Risk Score in the United States 
Population. PLoS One. 2012; 7doi: 10.1371/journal.pone.0044347
23. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease 
by risk factor burden at 50 years of age. Circulation. 2006; 113:791–8. DOI: 10.1161/
CIRCULATIONAHA.105.548206 [PubMed: 16461820] 
24. Stone NJ, Robinson FJ, H FA, et al. ACC/AHA Guideline on the Treatment of Blood Cholesterol 
to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol. 2013; Published 
Online First: 2013. doi: 10.1016/j.jacc.2013.11.002
25. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA. 2001; 285:2486–96. http://www.ncbi.nlm.nih.gov/pubmed/11368702. 
[PubMed: 11368702] 
26. Alberti K, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus 
Statement from the International Diabetes Federation. Diabet Med. 2006; 23:469–80. http://
www.ncbi.nlm.nih.gov/pubmed/16681555. [PubMed: 16681555] 
27. Maganga E, Smart LR, Kalluvya S, et al. Glucose Metabolism Disorders, HIV and Antiretroviral 
Therapy among Tanzanian Adults. PLoS One. 2015; 10:e0134410.doi: 10.1371/journal.pone.
0134410 [PubMed: 26287742] 
28. Hulten E, Villines TC, Cheezum MK, et al. Calcium score, coronary artery disease extent and 
severity, and clinical outcomes among low Framingham risk patients with low vs high lifetime 
risk: Results from the CONFIRM registry. J Nucl Cardiol. 2014; 21:29–37. DOI: 10.1007/
s12350-013-9819-7 [PubMed: 24385134] 
Kingery et al. Page 10
Heart. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
29. Paixao a RM, Ayers CR, Rohatgi A, et al. Cardiovascular Lifetime Risk Predicts Incidence of 
Coronary Calcification in Individuals With Low Short-Term Risk: The Dallas Heart Study. J Am 
Heart Assoc. 2014; 3:e001280–e001280. DOI: 10.1161/JAHA.114.001280 [PubMed: 25424574] 
Kingery et al. Page 11
Heart. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
KEY QUESTIONS
What is already known about this subject?
Data from the US and Europe demonstrate that HIV-infected adults have an increased 
incidence of myocardial infarction, stroke, and sudden cardiac death; however, data 
regarding the cardiovascular disease (CVD) risk in African populations is scant. 
Recently, leading researchers in this field have called for in depth study of risk and risk 
predictors in the understudied, low and middle income country population.
What does this study add?
We report 10-year, 30-year and lifetime cardiovascular risk scores calculated with 
Framingham and current ACC/AHA ASCVD guidelines in African HIV-infected 
patients. Our data is the first to identify that many African HIV-infected patients have a 
high lifetime risk of CVD, which develops rapidly within the first four years of ART 
initiation, but do not meet current treatment criteria due to low short-term risk scores.
How might this impact on clinical practice?
We provide clinicians with a newly identified, high-risk subpopulation of HIV-infected 
individuals in SSA who may be candidates for closer CVD risk factor monitoring. 
Furthermore, we demonstrate that blood pressure measurement may be an efficient way 
to screen for metabolic syndrome in severely resource limited settings.
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TABLE 1
Baseline characteristics of the 454 Tanzanian adult study participants
Variable
n (%)
Mean (SD)
HIV-negative Control
(n=153)
HIV-infected, ART-naive
(n=151)
HIV-infected, on ART
(n=150)
Female 94 (61.4%) 89 (58.9%) 115 (76.7%)^
Age (years) 40.5 (11.6) 38.5 (9.6) 42.6 (8.3)
Mode of Transportation
 Walking or bicycle 130 (85.0%) 110 (72.9%) 117 (78.0%)
 Motorized vehicle 23 (15.0%) 41 (27.1%) 33 (22.0%)
Current Smoker 5 (3.3%) 4 (2.7%) 0
Body Mass Index (BMI) (kg/m2) 24.1 (3.6) 22.5 (3.9) 24.8 (4.6)
 <18.5 kg/m2 5 (3.3%) 18 (11.9%) 4 (2.7%)
 18.5–24.9 kg/m2 104 (68.0%) 113 (74.8%) 80 (53.3%)
 25–29.9 kg/m2 33 (21.6%) 9 (6.0%) 45 (30.0%)
 ≥30 kg/m2 11 (7.2%) 11 (7.3%) 21 (14.0%)
Waist-hip ratio 0.84 (0.05) 0.85 (0.06) 0.86 (0.06)
 Central obesity (ATPIV*) 25 (16.3%) 14 (9.3%) 38 (25.3%)
 Central obesity (IDF**) 48 (31.4%) 45 (29.8%) 72 (48.0%)
Current CD4 T-cell count (cells/μL) NA 247.58 (184.42) 406.63 (197.88)
ART duration*** (months) NA NA 53.09 (21.63)
Protease Inhibitor use NA NA 18 (12.0%)
Diabetes Mellitus 8 (5.2%) 1 (0.7%) 27 (18.0%)
Hypertension# 25 (16.3%) 8 (5.3%) 43 (28.7%)
 Hypertension on treatment 4 (2.6%) 1 (0.7%) 10 (6.7%)
*ATP IV central obesity: Adult Treatment Panel IV, >88cm and >102cm for women and men, respectively
**
IDF: International Diabetes Federation, >80cm and >94cm for women and men, respectively
***ART duration: Antiretroviral therapy duration
#
Hypertension: systolic >140 mmHg or diastolic >90 mmHg
^p=0.002 (significant p-values reported for non-modifiable risk factors of age and sex)
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